New drug cocktail targets tough lung cancer
NCT ID NCT03333343
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests how safe and tolerable it is to combine the drug EGF816 with other targeted therapies (INC280, trametinib, ribociclib, gefitinib, or LXH254) in adults with advanced EGFR-mutant non-small cell lung cancer. About 105 participants will receive one of these combinations to see if it helps control the cancer. The goal is to find better treatment options for this specific type of lung cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTANT NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Ancona, AN, 60126, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Tainan, 704302, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.